Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $54
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. CLDX | 0.00 |
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:
CLDX) with a Overweight and raises the price target from $38 to $54.